22.8 C
August 18, 2022

Biofarm registers a net profit of lei 54.8 million in the first nine months of the year, up by 20% compared to the similar period of 2020


  • Biofarm registers a turnover of lei 179 million in the first nine months of the year, increasing by 16% compared to the same period in 2020
  • The net profit increased by 20%, to lei 54.8 million
  • EBITDA reached lei 75.6 million, up 20% compared to the first 9 months of 2020
  • In the CHC segment, Biofarm increased by 19% in value
  • Biofarm maintained its market share in volume, ranking 2nd



Biofarm (BIO stock symbol), one of Romania’s leading drug manufacturers, reports significant increases for the first nine months of the year compared to the same period in 2020. Biofarm recorded a turnover of lei 179 million in the first nine months of 2021 and a net profit of lei 54,8 million, up by 20%, compared to the same period last year. Biofarm, which this year marks 100 years of uninterrupted activity, reported EBITDA of over 75 million lei,  20% higher compared to the first nine months of last year.

 Over the last nine months we have completed the most important investment of the last 30 years in the local pharmaceutical industry – a production unit built from scratch, with modern facilities and equipment, we have completed the process of revitalizing the corporate image and strategic brands in the portfolio and we managed to consolidate our position in the top of the most important players in the local pharmaceutical industry, in the Consumer Healthcare (CHC) category. The financial results motivate us to continue Biofarm’s mission to do well through performance and with standards at the highest level “, said Cătălin Vicol, Biofarm’s general manager.

By volume, Biofarm ranks 2, with a 6 per cent increase from the same period last year, in line with category development. In value, Biofarm consolidated its sales to the final consumer, registering a 19% increase, compared to the purchase price in pharmacies.

Investments in marketing and promotion were increased compared to the same period last year in order to maintain the competitiveness of focus brands and support the launch of Biofen Extra, a combination of ibuprofen and paracetamol. The new product introduces Biofarm in the market segment with the highest business potential in the CHC category – drugs for pain therapy.

Biofarm’s portfolio covers the most important therapeutic areas in the Consumer Healthcare division – digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system, multivitamins, with over 20 representative brands.




Related posts

EUR 50 M EIB loan for Garanti Bank to support SMEs projects

Nine O' Clock

Bucharest rental prices down 8 pc


Strategikon Summit wraps up: Romania still has “certain lessons” to learn about good governance

Nine O' Clock